Thrombosis in ischemic heart disease

Archives of Internal Medicine

Volumn 156, Issue 13, 1996, Pages 1382-1394

  Ambrose, John A ^a,b   Weinrauch, Michael ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROTIC PLAQUE; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; HEART INFARCTION; HUMAN; HYPERCOAGULABILITY; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; THROMBOGENESIS;

CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; CORONARY THROMBOSIS; HUMANS; MYOCARDIAL ISCHEMIA; RECURRENCE;

EID: 0029967280     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.13.1382     Document Type: Review

References (166)

1. Quain R. On fatty diseases of the heart. Med Chr Trans. 1850;33:1217.
2. Osler W. Lectures on Angina Pectoris and Allied States. East Norwalk, Conn: Appleton & Lange: 1897.
3. Obrastzow WP, Straschesko ND. Zur Kenntnis der Thrombose Koronararterien des Herzens. Z Klin Med. 1910;71:116-132.
4. Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA. 1912;59: 2015-2020.
5. Freidberg CK, Horn H. Acute myocardial infarction not due to coronary artery occlusion. JAMA. 1939;112:1675-1679.
6. Branwood AW, Montgomery GL. Observations on the morbid anatomy of coronary disease. Scott Med J. 1956;1:367.
7. Erhardt LR, Lundman T, Mellstedt H. Incorporation of 1-125 labelled fibrinogen into coronary arterial thrombi in acute myocardial infarction in man. Lancet. 1973;1:387-390.
8. Roberts W, Buja LM. The frequency and significance of coronary artery thrombi and other observations in fatal acute myocardial infarction: a study of 107 necropsied cases using serial sections. Am J Med. 1972;52:425-443.
9. Chandler BA, Chapman I, Erhardt R, et al. Coronary thrombosis in myocardial infarction: report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol. 1974;34:823-832.
10. Dewood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
11. Rentrop P, Blanke H, Karsch KR, Kaiser H, Kostering H, Leitz K. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation. 1981;63: 307-317.
12. GISSI (Gruppo Italiano Per Lo Studio Della Streptochinasi Nell-Infarto Miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1: 397-402.
13. Kennedy WJ, Ritchie JL, Davis KB, Fritz JK. Western Washington Randomized Trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med. 1983;309:1477-1482.
14. Ambrose JA, Winters SL, Stern A, Eng A, Teicholz LE, Fuster V. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 1985;5:609-616.
15. Ambrose JA, Hjemdahl-Monsen CE. Borrico S, Gorlin R, Fuster V. Angiographic demonstration of a common link between unstable angina pectoris and non-Q wave acute myocardial infarction. Am J Cardiol. 1988;61:244-247.
16. Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med. 1986;315:913-919.
17. Bresnahan DR, Davis DR, Holmes DR Jr, Smith HC. Angiographic occurrence and clinical correlates of intraluminal coronary artery thrombus: role of unstable angina. J Am Coll Cardiol. 1985;6:285-289.
18. Ambrose JA. Plaque disruption and the acute coronary syndromes of unstable angina and myocardial infarction: if the substrate is similar, why is the clinical presentation different? J Am Coll Cardiol. 1992;19:1653-1658.
19. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Asociation. Circulation. 1994;89:2462-2478.
20. Stary HC, Chandler BA, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histopathological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355-1374.
21. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death and crescendo angina. Br Heart J. 1985;53:363-373.
22. Davies MJ. Thrombosis and coronary atherosclerosis. In: Julian DG, Kubler W, Norris RM, Swan HJC, Collen D, Verstraete M, eds. Thrombolysis in Cardiovascular Disease. New York, NY: Marcel Dekker Inc; 1989:25-33.
23. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogensis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
24. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophages, and smooth muscle cell content Br Heart J. 1993;69:377-381.
25. Falk E. Why do plaques rupture? Circulation. 1992;86(suppl 3):III-30-III-42.
26. Loree HM, Tobias BJ, Gibson LJ, Kamm RD, Small DM, Lee RT. Mechanical properties of model atherosclerotic lesion lipid pools. Arterioscler Thromb. 1994;14:230-234.
27. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362: 801-808.
28. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
29. Libby P. Molecular basis of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
30. Van de Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of the thrombosed coronary atherosclerotic plaques is characterised by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
31. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation. 1995;92:1084-1088.
32. Mehri Y, Lam JYT, Lacoste LL, Latour JG, Guidoin R, Waters D. Effects of thrombocytopenia and shear rate on neutrophil and platelet deposition on endothelial and medial arterial surfaces. Arterioscler Thromb. 1993;13:951-957.
33. Palabrica T, Lobb R, Furie B, et al. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992;359:848-851.
34. Richardson RD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;2:941-944.
35. Ambrose JA, Winters SL, Arora RR, et al. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol. 1986;7:472-478.
36. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-1166.
37. Nobuyoshi M, Tanaka M, Mosaka H, et al. Progression of coronary atherosclerosis: is coronary spasm related to progression? J Am Coll Cardiol. 1991;18:904-910.
38. Giroud D, Li JM, Urban P, Meier B, Ruthishauer W. Relation of the site of myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol. 1992;69: 729-732.
39. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J. 1988;9:1317-1323.
40. Hackett D, Verwilghen J, Davies G, Maseri A. Coronary stenosis before and after acute myocardial infarction. Am J Cardiol. 1989;63:1517-1518.
41. Serruys PW, Arnold AER, Brower RW, et al, for the European Co-operative Study Group for Recombinant Tissue-Type Plasminogen Activator. Effect of continued rt-PA administration on the residual stenosis after initially successfull recanalization in acute myocardial infarction: a quantitative coronary angiography study of a randomized trial. Eur Heart J. 1987;8:1172-1181.
42. Davies SW, Marchant B, Lyons JP, et al. Coronary lesion morphology in acute myocardial infarction: demonstration of early remodelling after streptokinase treatment. J Am Coll Cardiol. 1990;16:1079-1086.
43. Veen G, Meijer A, Werter CJPJ, et al. Dynamic changes of culprit lesion morphology and severity after successful thrombolysis for acute myocardial infarction: an angiographic follow up study. J Am Coll Cardiol. 1994;23:147A. Abstract.
44. Brown BG, Gallery CA, Badger RS, et al. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation. 1986;73:653-661.
45. Moise A, Theroux P, Taeymans Y, et al. Unstable angina and progression of coronary atherosclerosis. N Engl J Med. 1983;309:685-689.
46. Ambrose JA, Winters SL, Arora RR, Ricco A, Gorlin R, Fuster V. Angiographic evolution of coronary morphology in unstable angina. J Am Coll Cardiol. 1986;7:472-478.
47. Muller JE, Abela GS, Nesto RW, Toller GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 1994;23:809-813.
48. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and atable atherosclerotic lesions: a structural analysis with histopathological correlation. Circulation. 1993;87:1179-1187.
49. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
50. Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res. 1992;71:850-858.
51. Lee RT, Grodzinsky AJ, Frank EH, Kamm RD, Schoen FJ. Structure-dependent dynamic mechanical behavior of fibrous caps from human atherosclerotic plaques. Circulation. 1991;83: 1764-1770.
52. Maclsaac AL, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol. 1993;22:1228-1241.
53. Taeymans Y, Theroux P, Lesperance J, Waters D. Quantitative angiographic morphology of the coronary artery lesions at risk of thrombotic occlusion. Circulation. 1992;85:78-85.
54. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Pathogenesis of coronary artery disease and the acute coronary syndromes, 2, N Engl J Med. 1992;326:310-318.
55. von Rokitansky C: Day GE, trans. A Manual of Pathological Anatomy. London, England: The Sydenham Society; 1852.
56. Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol. 1946;58:207-213.
57. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation. 1988;77:1213-1220.
58. Davies MJ, Bland JM, Hangartner JWR, Angelini A, Thomas AC. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J. 1989;10:203-208.
59. Wilcox JN. Thrombotic mechanisms in atherosclerosis. Coron Artery Dis. 1994;5:223-229.
60. Bini A, Fenoglio J, Mesa-Tejada R, Kudryk B, Kaplan K. Identification and distribution of fibrinogen, fibrin and fibrin(ogen) degradation products in atherosclerosis: use of monoclonal antibodies. Arteriosclerosis. 1989;9:109-121.
61. Badimon L, Badimon JJ, Fuster V. Pathogenesis of thrombosis. In: Foster V, Verstratete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders Co; 1992;17-39.
62. Woolf N, Davies MJ. Interrelationship between atherosclerosis and thrombosis. In: Fuster V, Verstratete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders Co: 1992:41-77.
63. Pepine CJ, Hirshfeld JW, Macdonald RG, et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. Circulation. 1990;81:1753-1761.
64. Serruys PW, Luijten HE, Beatt KJ. Incidence of restenosis after successful coronary angioplasty: a time related phenomenon: a quantitative angiographic study in 342 consecutive patients at 1, 2, 3. and 4 months. Circulation. 1988;77:361-371.
65. Califf RM, Ohman EM, Frid DJ, Hillegass WB. Restenosis: the clinical issues. In: Topol EJ, ed. Textbook of Intervention Cardiology. Philadelphia, Pa: WB Saunders Co; 1990:415-435.
66. Rensing BJ, Serruys PW, Beatt KJ, Suryapranata H, Laarman GJ, deFeyter PJ. Densitometrically observed differences in elastic recoil of the 3 main coronary arteries after coronary angioplasty. J Am Coll Cardiol. 1990;15: 1039-1044.
67. Nobuyoshi M, Takeshi K, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographie follow-up of 229 patients. J Am Coll Cardiol. 1988;12:616-623.
68. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:101B-110B.
69. Uchida Y, Hasegawa K, Kawamura K, Shibuya I. Angioscopic observation of the coronary Iuminal changes induced by percutaneous transluminal coronary angioplasty. Am Heart J. 1989; 117:769-776.
70. Rodriguez AE, Palacios IF, Fernandez MA, Larribau M, Giraudo M, Ambrose JA. Time course and mechanism of early luminal diameter loss after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1995;76:1131-1134.
71. Mintz GS, Popma JJ, Pichard AD, et al. Patterns of target lesion calcification in coronary artery disease. J Am Coll Cardiol. 1995:154A.
72. Clowes A, Clowes M, Reidy M. Kinetics of cellular proliferation after arterial injury. Lab Invest. 1986;54:295-303.
73. Woolf N, Davies M, Bradley J. Medial changes following experimentally induced thrombosis in the pig aorta. J Pathol. 1971;105:205-209.
74. Ip JH, Fuster V, Israel D, Badimon L, Badimon JJ, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. J Am Coll Cardiol. 1991;17 (suppl):77B-88B.
75. Heras M, Chesebro JH, Webster MWI. Hirudin, heparin and placebo during deep arterial injury in the leg: the in vivo role of thrombin in platelet mediated thrombosis. Circulation. 1990;82:1476-1484.
76. Friedman RJ, Stemerman MB, Wenz B, et al. The effect of thrombocytopenia on experimental atherosclerotic lesion formation in rabbits. J Clin Invest. 1977;60:1191-1201.
77. Harker LA. Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angiography. Am J Cardiol. 1987;60: 20B-28B.
78. Barstad RM, Hamers MJ, Kierulf P, Westvik AB, Sakariassen KS. Procoagulant human monocytes mediate tissue factor/factor Vlla-dependent platelet-thrombus formation when exposed to flowing nonanticoagulated human blood. Arterioscler Thromb Vasc Biol. 1995; 15:11-16.
79. Califf RM, Fortin DF, Frid DJ, et al. Restenosis after coronary angioplasty: an overview. J Am Coll Cardil. 1991;17:2B-13B.
80. Thornton MA, Gruentzig AR, Hollman Y, King SB, Douglas JS. Coumadin and aspirin in the prevention of recurrence after transluminal coronary angioplasty: a randomized study. Circulation. 1984;69:721-727.
81. Topol EJ, Califf RM, Weisman HF, et al, on behalf of the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical stenosis: results at six months. Lancet. 1994; 343:881-886.
82. Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodies to platelet GP IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci. 1991; 614:193-213.
83. The Multicenter Italian Research Trial with trapidil in the prevention of restenosis after PTCA (STARC). Trapidil (platelet-derived growth factor inhibitor) prevents restenosis after PTCA. Circulation. 1993;88(pt 2):1-594.
84. Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V. Platelet thrombus formation on collagen type 1: a model of deep vessel injury: influence of blood rheology, von Willebrand factor, and blood coagulation. Circulation. 1988;78:1432-1442.
85. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1564-1569.
86. Drake TA, Morrisseg JH, Edgington TS. Selective cellular expression of tissue factor in human tissue: implication for disorders of hemostasis and thrombosis. Am J Pathol, 1989;134: 1087-1097.
87. Annex BH, Denning SM, Channon KM, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 1995;91:619-622.
88. Bauer KA, Weitz JI. Laboratory markers of coagulation and fibrinolysis. In: Colman R, ed. Hemostasis and Thrombosis. 3rd ed. New York, NY: JB Lippincott; 1994:1197-1210.
89. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation. 1994;89:1951-1957.
90. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from Framingham Study. Am Heart J. 1987;113:1006-1010.
91. . Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J. 1994;128:7-11.
92. Meade TW, North WRS, Chakrabarti R, et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980; 1:1050-1054
93. Alderman MH, Madhaven S, Ooi WL. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
94. Bogalusa Heart Study. Racial (black/white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Circulation. 1991;84:160-167.
95. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313:1557-1563.
96. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:51-68.
97. Oshima S, Ogawa H, Yasue H, Okumura K, Matsuyama M, Miyagi H. Increased plasma fibrinopeptide A levels during attacks induced by hyperventilation in patients with coronary vasospastic angina. J Am Coll Cardiol. 1989;14: 150-154.
98. Moncada S, Gryglewski R, Bunting S, Vane SR. An enzyme isolated from arteries transforms prostaglandin endoperoxidase to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
99. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 299:372-376.
100. Ambrose JA, Hjemdahl-Monsen CE. Arteriographic anatomy and mechanisms of myocardial ischemia in unstable angina. J Am Coll Cardiol. 1987;9:1397-1402.
101. Dewood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non-Q wave myocardial infarction. N Engl J Med. 1986; 315:417-423.
102. Gorlin R, Fuster V, Ambrose JA. Anatomic-physiologic links between acute coronary syndromes. Circulation. 1986;74:6-9.
103. Mehran R, Ambrose JA, Bongu RM, et al. Angioplasty of complex lesions in ischemic rest angina: results of the TAUSA trial. J Am Coll Cardiol. 1995;26:1047-1053.
104. Ambrose JA, Hjemdahl-Monsen C. Acute ischemic syndromes: coronary pathophysiology and angiographic correlations. In: Gersh B, Rahematoola S, eds. Acute Myocardial Infarction. New York, NY: Elsevier Science Publishing Co Inc; 1991:64-77.
105. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation. 1988;77:1213-1220.
106. Dacanay S, Kennedy HJ, Uretz E, Parrillo JE, Klein LW. Morphological and quantitative angiographic analyses of progression of coronary stenoses: a comparison of Q-wave and non-Q-wave myocardial infarction. Circulation. 1994; 90:1739-1746.
107. Murry CE, Jennings RB, Reimer KA, Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74:1124-1136.
108. Liberthson RR, Nagel EL. Hirschman JC, Nusnfeld SR, Blackbourne BD, Davis JH. Pathophysiologic observations in prehospital ventricular fibrillation and sudden cardiac death. Circulation. 1974;49:790-798.
109. Davies MJ, Thomas A. Thrombosis and acute coronary lesions in sudden cardiac ischemic death. N Engl J Med. 1984;310:1137-1114.
110. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation. 1995;92:1701-1709.
111. Davies MH, Bland JM, Hangartner JRW, Angelini A, Thomas AC. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J. 1989;10:203-208.
112. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med. 1983;309:396-403.
113. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfipyrazone or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med. 1985;313:1369-1375.
114. Theroux P, Quimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105-1111.
115. Wallentin L for the RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-830.
116. Theroux P, Waters D, Qui S, McCans J, de-Guise P, Juneau M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 1993; 88(pt 1):2045-2048.
117. Cohen M, Adams PC, Parry G, et al, and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non-prior aspirin users: primary end points analysis from the ATACS trial. Circulation. 1994;89:81-88.
118. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. 1992;327:141-145.
119. Willerson JT, Casscells W. Thrombin inhibitors in unstable angina rebound or continuation of angina after argatroban withdrawal? J Am Coll Cardiol. 1993;21:1048-1051.
120. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation. 1994;89:1557-1565.
121. Lidon RM, Theroux P, Juneau M, et al. Initial experience with a direct antithrombin, hirulog, in unstable angina. Circulation. 1993;88:1495-1501.
122. Chesebro JH, Goldhelyi P, Fuster V. Pathogenesis of thrombosis in unstable angina. Am J Cardiol. 1991;68:2B-10B.
123. Theroux P, Kleiman N, Shah PK, et al. A doubleblind, heparin-controlled study of MK-852 in unstable angina. Circulation. 1993;88(pt 2):1-201.
124. Ferguson JJ. Impact II results announced. Circulation. 1995;92:697.
125. Ambrose JA, Alexopoulos D. Thrombolysis in unstable angina: will the beneficial effects of thrombolytic therapy in myocardial infarction apply to patients with unstable angina? J Am Coll Cardiol. 1989;13:1666.
126. Waters D, Jules YT, Lam JY. Is thrombolytic therapy striking out in unstable angina? Circulation. 1992;86:1642-1643.
127. Mabin TA, Holmes DR, Smith HC, et al. lntracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1985;5: 198-202.
128. Arora RR, Platko WP, BhadwarK, Simfendorfer C. Role of intracoronary thrombus in acute complications during percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn. 1989;16:226-229.
129. Laskey MA, Deutsch E, Hirschfeld JW Jr, Kussmaul WG, Barnathan E, Laskey WK. Influence of heparin on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol. 1990;65: 179-182.
130. Laskey MAL, Deutsch E, Barnathan E, Laskey WK. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol. 1990;65:1425-1429.
131. Chapekis AT, George BS, Candela RJ. Rapid thrombus dissolution by continuous infusion of urokinase through an intracoronary perfusion wire prior to and following PTCA: results in native coronaries and patent saphenous vein grafts. Cathet Cardiovasc Diagn. 1991;23:89-92.
132. EPIC Investigators. Use of monoclonal antibody directed against the platelet GP IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
133. Lincoff AM, Califf RM, Anderson K. Weisman HF, Topol EJ, for the EPIC Investigators. Striking clinical benefit with platelet GP IIb/IIIa inhibition by c7E3 among patients with unstable angina pectoris: outcome in the EPIC trial. Circulation. 1994;90:(pt 2):1-21A.
134. Laffel GL, Braunwald E. Thrombolytic therapy: A new strategy for treatment of acute myocardial infarction. N Engl J Med. 1984;311:710-717.
135. Gruppo Italiano Per Lo Studio Delia Sopravvivenza Nell' Infracto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65-71.
136. The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation. 1994;89:1545-1556.
137. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
138. ISIS 2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS 2. Lancet. 1988; 2:349-360.
139. Yasuda T, Gold HK, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inbitor and a monoclonal antiplatelet glycoprotein IIb/IIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol. 1990; 16:714-722.
140. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation. 1991;83:1048-1056.
141. Sobel BE. Intracranial bleeding, fibrinolysis, and anticoagulation. Circulation. 1994;90:2147-2152.
142. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med, 1993;329: 1615-1622.
143. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction, N Engl J Med. 1993;328:673-679.
144. The Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
145. Peto R, Gray R, Collins R, et al. A randomized trial of the effects of prophylactic daily aspirin among male British doctors. BMJ. 1988;296: 313.
146. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659-675.
147. Beta-Blocker Pooling Project Research Group, The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post-infarction patients. Eur Heart J. 1988;9:8-16.
148. Hearne SE, Ohman EM, Teo KK. Adjunctive agents to reduce ischemia, preserve myocardial functions and reduce mortality. In: Califf R, Mark D, Wagner G, eds. Acute Coronary Care. 2nd ed. St Louis, Mo: Mosby-Year Book; 1995: 355-369.
149. Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-367.
150. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril in mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1991;325:293-302.
151. ISIS-4 Collaborative Group. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet. 1995;92:1068-1073.
152. Opie LH, Messerli FH. Nifedipine and mortality. Circulation. 1995;92:1068-1073.
153. Yusuf S. Calcium antagonists in coronary artery disease and hypertension. Circulation. 1995: 92:1079-1082.
154. Nabulsi AA, Folsom AR, White A, et al. Association of hormone replacement therapy in various cardiovascular risk factors in post-menopausal women. N Engl J Med. 1993;328: 1070-1075.
155. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 1992;20:452-457.
156. Lipid Research Clinics Program. The Lipid Research Clinics' Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:351.
157. Mannienn V, Elo MO, Frick L. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988; 260:641-651.
158. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
159. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease (based on FATS and other studies). Circulation. 1993;87:1781-1791.
160. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis and Infarction Trial (CCAIT). Circulation. 1993;89:959-968.
161. Pearson TA, Marx HJ. The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications. Am J Cardiol. 1993;72:1072-1073.
162. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
163. Treasure CB, Klein LJ, Weintraub WS, et al. Benelicial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332: 481-487.
164. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol lowering decreased size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation. 1994;89:1530-1538.
165. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
166. Davies MJ. Thrombosis and Coronary Atherosclerosis in Thrombolysis in Cardiovascular Disease. New York, NY: Marcel Dekker Inc; 1989: 25-43.